BEIGF News and Press, BeiGene From 08/06/25

2025-08-06 13:37:33 ET More on BeiGene BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance BeiGene Q2...

2025-08-06 13:36:36 ET BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call August 6, 2025 8:00 A.M. ET Company Participants Aaron Rosenberg - Chief Financial Officer Daniel Maller - Head of Investor Relations John V. Oyler - Co-Founder, Executive Chairman & CEO ...

2025-08-06 07:58:19 ET More on BeiGene BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance Bei...

2025-08-06 07:52:27 ET More on BeOne Medicines BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit BeiGene Q2 2025 Earnings Preview BeOne Medicines' Tevimbra gets CHMP...

2025-07-10 10:51:55 ET More on BeiGene BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript BeOne gets FDA nod for table...

2025-07-08 09:00:00 ET Showcase Intro In June, we welcomed a record number of new analysts - 48 in all - who published their first-ever article on Seeking Alpha. In this article, our editors highlight some of the best ideas from these new analysts and introduce them. The first t...

2025-07-07 09:30:00 ET Jazz Pharmaceuticals plc's (NASDAQ: JAZZ ) stock price has continued to fluctuate between $97 and $120 over the past three months, even as it has made significant progress in developing its oncology franchise.... Read the full article on Seeking Alph...

2025-06-17 21:14:09 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 05/15/2025. The 13F portfolio value decreased from $...

2025-06-16 11:06:08 ET ... Read the full article on Seeking Alpha For further details see: BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium

2025-05-27 09:06:12 ET More on BeiGene BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025 Drugmakers rebound after White H...